ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ANIP / dividends
KLRA (45) NUVB (19) STOK (46) MLYS (33) ⌘ Pro Terminal →

ANI Pharmaceuticals Inc. (ANIP) Dividend Safety Gauge & 10-Year DRIP Compounder

$70.67 -1.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $70.30

ANI Pharmaceuticals Inc. (ANIP) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $1.65B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANIP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ANIP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ANI Pharmaceuticals Inc. (NASDAQ: ANIP) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $70.67 (-1.85% 1D, market cap $1.65B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, ANIP ranks #140 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ANIP compare to KLRA and NUVB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANIP carries a Roarable C (63/100 RQD), trailing P/E of 21.5x, gross margin of —, and ROIC of 16.0%. By comparison, KLRA (Kailera Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.67B) and NUVB (Nuvation Bio Inc. (Class A)) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANIP?
▼

Per ANIP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001023024), ANI Pharmaceuticals Inc. generated $883.4M in revenue (+43.8% YoY), $78.0M in net income, and $171.4M in free cash flow against $1.44B in total assets and $291.8M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $70.30 (-0.52%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 19.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510063
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C · Rk C
Cash (15)Whales (6)SEC (14)Macro (11)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+2.2% Base Target
$100 Bull$72 Base$56 Bear
📬 FREE ANIP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANIP)Realized 20D OHLCV Swing Band: ±5.6%
Deterministic 5-Pillar Attribution (63/100 Composite)
🔍 WHY ANIP SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (27% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+15/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 19.4% FCF Margin ($171.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
71
Grade B$70.84+2.6% Next Q
Q2 (-2Q)
68
Grade B-$72.67-2.1% Next Q
Q3 (-1Q)
66
Grade B-$71.17-0.7% Next Q
Current
63
Grade C$70.67+0.9% Hist 90D α
Trajectory: B (71) → C (63)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ANIP Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, ANIP faces multiple-compression risk if 21.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($72.87) or 200D SMA ($77.53) invalidates the momentum regime and cuts Target Base ($72.26) toward Bear Floor ($56.36).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANIP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ANIP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 63%NO 37%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.87% Total Yield
0.07% Cash ($0.05/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
88/100 • FORTRESS PAYOUT
FREE CASH FLOW PAYOUT RATIO
14% of FCF
8 consecutive years of payout growth
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.4% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,659

Est. Year-10 Shareholder Yield: $854/yr
$11.6K
Yr 1
$13.5K
Yr 2
$15.8K
Yr 3
$18.4K
Yr 4
$21.4K
Yr 5
$24.9K
Yr 6
$29.0K
Yr 7
$33.7K
Yr 8
$39.2K
Yr 9
$45.7K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in ANIP & A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on ANIP and its top sector peer
  • ✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
  • ✓Includes nightly RQD rating-change & forensic signal email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ANIP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.15%▼ DESCENDING CHANNEL
2026-11-03O $73.16H $73.16L $70.67C $70.67VOL 286.9K
RES: $74.89SUP: $63.97SMA50: $72.87SMA200: $77.53
$89.03$83.76$78.49$73.22$67.94RES $74.89SUP $63.97$70.672026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANIP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANIP Butterfly Map → + Track ANIP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
15.2%/yr Implied 5Y Growth

vs. +43.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ANIP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANIP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANIP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANIP)

Health Care Rank #140 of 1015 ⚔️ KLRA vs ANIP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANIP vs. KLRA, NUVB, STOK, MLYS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, ANI Pharmaceuticals Inc. (ANIP) ranks #140 by composite RQD confidence (63/100, grade C) and #287 by equity capitalization ($1.65B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ANIP ACTIVE
ANI Pharmaceuticals Inc.
C 63/100 21.5x — 16.0% -1.85% $1.65B Benchmark Subject
KLRA
Kailera Therapeutics Inc.
D 45/100 — — — -5.52% $1.67B /klra-vs-anip →
NUVB
Nuvation Bio Inc. (Class A)
E 19/100 — — -35.0% -3.57% $1.67B /nuvb-vs-anip →
STOK
Stoke Therapeutics Inc.
D 46/100 — — -6.1% +0.72% $1.70B /stok-vs-anip →
MLYS
Mineralys Therapeutics Inc.
E 33/100 — — -28.4% -14.47% $1.61B /mlys-vs-anip →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001023024 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ANI Pharmaceuticals Inc. (ANIP) reported GAAP revenue of $883.4M (+43.8% vs. FY2024 revenue of $614.4M , and +81.5% cumulative change since FY2023) , GAAP net income of $78.0M, operating cash flow of $185.2M, and free cash flow of $171.4M (+258.7% YoY). On the balance sheet, ANIP closed FY2025 with $1.44B in total assets against $291.8M in total debt (Altman Z-Score: 2.36, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $883.4M $78.0M $185.2M $171.4M $1.44B $291.8M
FY2024 (FY) 2024-12-31 $614.4M -$19.0M $64.0M $47.8M $1.28B $309.1M
FY2023 (FY) 2023-12-31 $486.8M $19.0M $119.0M $119.0M — —

3. ANIP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANIP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ANI Pharmaceuticals Inc. (NASDAQ: ANIP) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $70.67 (-1.85% 1D, market cap $1.65B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, ANIP ranks #140 in composite RQD confidence.

How does ANIP compare to KLRA and NUVB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANIP carries a Roarable C (63/100 RQD), trailing P/E of 21.5x, gross margin of —, and ROIC of 16.0%. By comparison, KLRA (Kailera Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $1.67B) and NUVB (Nuvation Bio Inc. (Class A)) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANIP?

Per ANIP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001023024), ANI Pharmaceuticals Inc. generated $883.4M in revenue (+43.8% YoY), $78.0M in net income, and $171.4M in free cash flow against $1.44B in total assets and $291.8M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANIP trading relative to its 50-day, 200-day, and 52-week technical levels?

ANIP last traded at $70.67 (-1.85% on volume of 514,740 shares), positioning the stock -3.02% below its 50-day simple moving average ($72.87) and -8.85% below its 200-day simple moving average ($77.53). Across its 52-week range of $69.58 to $95.57, ANIP sits at the 4.2% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±5.6% ($66.71 to $74.63).

Direct Sub-Reports: ANIP RQD Cockpit ANIP 12M Forecast ANIP Earnings & Move ANIP Dividends & DRIP ANIP Insiders & 13F ANIP Whale Options ANIP Profit Sankey ANIP News & Why
ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ SEC XBRL & RQD VERIFIED

ANIP — ANI Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ANI Pharmaceuticals Inc. (ANIP) earns a live Roarable RQD composite score of 63/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $70.67 (-1.85% 1D, market capitalization $1.65B).

  • Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 16.0%, gross margin of —, operating margin of 12.6%, and free cash flow yield of 10.20%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.36, Piotroski F-Score of 8/9, and Debt/Equity of 0.54x.

2. Business Model, Unit Margins & SEC Financial Trajectory

ANI Pharmaceuticals Inc. (ANIP) is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The company reported FY 2025 revenue of $883.4M, indicating a material operating scale.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ANI Pharmaceuticals Inc. (ANIP) reported $883.4M in annual revenue (up from $614.4M in FY2024, +43.8% YoY) and $78.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($486.8M revenue, $19.0M net income) through FY2025, ANIP scaled operating cash flow to $185.2M and free cash flow to $171.4M, backed by $1.44B in total assets against $291.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 63/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $69.58 – $95.57 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 21.5x trailing P/E and 13.7x EV/EBITDA against 12.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for sector correlations or second-order bottlenecks beyond the general sector classification of Health Care / Biotechnology: Pharmaceutical Preparations.

  • Key Question #1: Can ANIP sustain or expand its 12.6% operating margin and 16.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $883.4M and free cash flow of $171.4M, how will capital allocation balance growth reinvestment against $291.8M in total debt?
  • Key Question #3: How sensitive is ANIP's 18.1x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ANIP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ANI Pharmaceuticals Inc. (ANIP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ANIP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANIP Bull vs. Bear Conversation Board — What's Your Call at $70.67?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANIP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ANIP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $89.28 (+24.0%)
📌 Pinned Debate

FY 2025 net income of $78.0M, up from a -$19.0M loss in FY 2024, paired with 16% ROIC and a 10.2% FCF yield.

Here is why I am bullish on ANIP here at $72.00: FY 2025 net income of $78.0M, up from a -$19.0M loss in FY 2024, paired with 16% ROIC and a 10.2% FCF yield.. Compare ANIP's 12.6% operating margin and 16.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $68.40 are getting bought.

SectorRotator 🐂 BULL

@ShortSeller_Dan Fair point on 21.5x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $59.04 (-18.0%)
Spot @ $72.00

Whale 13F flow scores only 7/20 and beta of 1.0 gives no defensive or macro tailwind, leaving the stock priced at 21.5x trailing earnin

Sitting on the sidelines or leaning short ANIP above $72.00. Whale 13F flow scores only 7/20 and beta of 1.0 gives no defensive or macro tailwind, leaving the stock priced at 21.5x trailing earnings.. Until Fundamental Cash Engine (15/20) and FCF yield (10.2%) inflect higher, upside is capped near $95.57.

LIVE TAPE